In order to overcome these limitations, we recently analysed the pharmacokinetic and pharmacodynamic profile of gemcitabine in LSLKrasG12D/+; LSL-Trp53R172H/+; Pdx-1-Cre (KPC) tumours over time using LC-MS/MS as the most sensitive detection method for gemcitabine metabolites. Here, PDX1 is linked to neoplasm.